qPharmetra supports drug development companies with their strategic decision-making during all phases of clinical development. Clinical data on efficacy and safety of new drugs are integrated into mathematical models that are used to simulate future drug development scenarios. qPharmetra consultants perform these in silico analyses, and, combined with their medical, pharmacological and statistical expertise, are able to support their clients before, during and after clinical studies to optimize the drug development process